Clinical Trial Update: D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC

View source ↗

Summary

A recruiting clinical trial is evaluating D-TACE-HAIC in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• D-TACE-HAIC
• Envafolimab (envafolimab)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Fujian Provincial Hospital | Conditions: Intrahepatic Cholangiocarcinoma | Status: RECRUITING